支原體檢測市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、技術、應用、最終用戶、地區、競爭細分，2020-2030 年

2024 年全球支原體檢測市場價值為 10.907 億美元，預計在預測期內將實現強勁成長，到 2030 年的複合年成長率為 13.45%。全球支原體檢測市場是診斷和傳染病管理領域內一個充滿活力且快速發展的產業。支原體是一種因缺乏細胞壁而聞名的細菌屬，可以感染各種宿主生物，包括人類、動物和細胞培養。支原體污染對研究、生物製藥製造和臨床診斷構成重大威脅，因此支原體檢測成為品質控制和安全保證的重要組成部分。

主要市場促進因素

新興生物製藥和生技產業

主要市場挑戰

發展中地區的成本限制

主要市場趨勢

分子診斷的快速應用

全球支原體檢測市場的一個重要趨勢是分子診斷的快速採用，特別是基於聚合酶鏈反應 (PCR) 的方法。

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：支原體檢測市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品（儀器、試劑盒及試劑）
  • 依技術分類（PCR、ELISA、酵素法、DNA 染色、其他）
  • 按應用（細胞株測試、生物生產測試、其他）
  • 按最終用戶（學術研究機構、細胞庫、合約研究組織、製藥和生物技術公司等）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美支原體檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第7章：歐洲支原體檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太地區支原體檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美支原體檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲支原體檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球支原體檢測市場：SWOT 分析

第 14 章：競爭格局

• Agilent Technologies Inc
• ATCC
• Bionique Testing Laboratories Inc.
• Charles River Laboratories International Inc.
• Lonza Group Ltd
• Merck KGaA
• Bionique Testing Laboratories Inc.
• PromoCell GmbH
• Thermo Fisher Scientific Inc.
• Sartorius AG

第 15 章：策略建議

第16章調查會社について,免責事項

Global Mycoplasma Testing Market was valued at USD 1090.70 Million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 13.45% through 2030. The Global Mycoplasma Testing Market is a dynamic and rapidly evolving sector within the broader field of diagnostics and infectious disease management. Mycoplasma, a genus of bacteria known for their lack of a cell wall, can infect various host organisms, including humans, animals, and cell cultures. Mycoplasma contamination poses a significant threat to research, biopharmaceutical manufacturing, and clinical diagnostics, making mycoplasma testing an essential component of quality control and safety assurance.

Key Market Drivers

Rising Biopharmaceutical and Biotechnology Industries

The rapid expansion of the biopharmaceutical and biotechnology industries is a key driver of the Global Mycoplasma Testing Market. Over the past few years, the number of FDA-registered manufacturing facilities in the U.S. producing human-use medicines, along with their associated testing, labeling, and packaging operations, has surged by more than 50%. Biopharmaceutical companies are actively investing in new construction, facility expansions, and technology upgrades to support the production of next-generation therapies, ensuring a robust and scalable supply chain for advanced treatments across the country. These industries rely heavily on cell culture-based production processes, where contamination can compromise product integrity, regulatory compliance, and patient safety. Mycoplasma, a frequent and insidious contaminant, necessitates stringent testing protocols to ensure the purity and efficacy of biopharmaceutical products. The rising investments, increasing adoption of biologics, and growing need for quality control in biotech processes directly fuel the demand for mycoplasma testing. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and biosimilars, are revolutionizing modern medicine. These products rely on mammalian cell cultures for production, making them highly susceptible to mycoplasma contamination. The growing adoption of biologics for treating chronic diseases, including cancer, autoimmune disorders, and infectious diseases, necessitates stringent contamination control measures. As patents for biologic drugs expire, biosimilar manufacturers must comply with regulatory guidelines for mycoplasma testing to ensure their products meet the same safety and efficacy standards as originator biologics. With global sales of biologics projected to surpass traditional pharmaceuticals, mycoplasma testing has become an integral part of quality assurance in drug development and production.

Key Market Challenges

Cost Constraints in Developing Regions

One of the significant challenges in expanding the mycoplasma testing market is the cost associated with acquiring and implementing testing solutions. In developing regions with limited healthcare budgets, investing in expensive mycoplasma testing equipment and reagents can be prohibitive.

Many developing countries allocate a substantial portion of their healthcare budgets to basic healthcare needs like vaccinations and infectious disease control. This leaves limited resources for advanced diagnostic technologies, including mycoplasma testing. Establishing a mycoplasma testing infrastructure, including purchasing specialized equipment and training personnel, requires a considerable initial investment that some regions may struggle to afford. Continuous testing relies on a steady supply of costly reagents and consumables, which can be a financial burden for healthcare facilities in resource-constrained areas.

Key Market Trends

Rapid Adoption of Molecular Diagnostics

One significant trend in the Global Mycoplasma Testing Market is the rapid adoption of molecular diagnostics, particularly Polymerase Chain Reaction (PCR)-based methods.

Molecular diagnostic techniques, such as PCR, offer unparalleled sensitivity and specificity in detecting mycoplasma DNA. They can identify even low levels of contamination quickly and accurately. Molecular tests provide rapid results, often within hours, compared to traditional culture-based methods that can take days or even weeks. This speed is crucial in maintaining the efficiency of biopharmaceutical production and research. Automated molecular testing platforms allow for high throughput, making them suitable for large-scale testing in biopharmaceutical manufacturing facilities. PCR-based methods reduce the risk of false positives associated with traditional culture-based techniques, as they do not rely on the growth of mycoplasma cells.

Key Market Players

• Agilent Technologies Inc
• ATCC
• Bionique Testing Laboratories Inc.
• Charles River Laboratories International Inc.
• Lonza Group Ltd
• Merck KGaA
• Bionique Testing Laboratories Inc.
• PromoCell GmbH
• Thermo Fisher Scientific Inc.
• Sartorius AG

Report Scope:

In this report, the Global Mycoplasma Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Mycoplasma Testing Market, By Product:

• Instruments
• Kits and Reagents

Mycoplasma Testing Market, By Technology:

• PCR
• ELISA
• Enzymatic Methods
• DNA Staining
• Other

Mycoplasma Testing Market, By Application:

• Cell Line Testing
• Bioproduction Testing
• Other

Mycoplasma Testing Market, By End-User:

• Academic Research Institutes
• Cell Banks
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies
• Others

Mycoplasma Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Mycoplasma Testing Market.

Available Customizations:

Global Mycoplasma Testing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Mycoplasma Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Kits and Reagents)
  • 5.2.2. By Technology (PCR, ELISA, Enzymatic Methods, DNA Staining, Other)
  • 5.2.3. By Application (Cell Line Testing, Bioproduction Testing, Other)
  • 5.2.4. By End-User (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Mycoplasma Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Mycoplasma Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Mycoplasma Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Mycoplasma Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Mycoplasma Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Mycoplasma Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Mycoplasma Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Mycoplasma Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. France Mycoplasma Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Mycoplasma Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Mycoplasma Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Mycoplasma Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Mycoplasma Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Mycoplasma Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Mycoplasma Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Mycoplasma Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Mycoplasma Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Mycoplasma Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Mycoplasma Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Mycoplasma Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Mycoplasma Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Mycoplasma Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Mycoplasma Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Mycoplasma Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Mycoplasma Testing Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Agilent Technologies Inc
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. ATCC
• 14.3. Bionique Testing Laboratories Inc.
• 14.4. Charles River Laboratories International Inc.
• 14.5. Lonza Group Ltd
• 14.6. Merck KGaA
• 14.7. Bionique Testing Laboratories Inc.
• 14.8. PromoCell GmbH
• 14.9. Thermo Fisher Scientific Inc.
• 14.10.Sartorius AG

15. Strategic Recommendations

16. About Us & Disclaimer